CELC Celcuity

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

  • A fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Thursday, April 11, 2024. A live webcast will be available using this weblink: ; and
  • A fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 17, 2024. A live webcast will be available using this weblink: .

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at with a replay available shortly after the live events.

About Celcuity 

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at . A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies.  Further information about Celcuity can be found at . Follow us on  and .

Contacts: 

Celcuity Inc. 

Brian Sullivan,  

Vicky Hahne,  

(763) 392-0123 

ICR Westwicke 

Maria Yonkoski,    

(203) 682-7167



EN
04/04/2024

Underlying

CELCCelcuity

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celcuity

 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Resul...

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information...

August 7, 2025 1 EN
Free Trial
CELC CELCUITY

Celcuity Inc: 1 director

A director at Celcuity Inc sold 109,325 shares at 44.074USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

07/30/25 July 30, 2025 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.75...

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public offering of $175,000,000 aggregate principal amount of its 2.750% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”), and its underwritten pub...

July 30, 2025 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Sen...

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public offerings of $150,000,000 aggregate principal amount of its convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $75,000,000 of shares of its common stock (the “Common Stock” and, such offerin...

July 28, 2025 1 EN
 PRESS RELEASE
Free
CELC CELCUITY

Celcuity Announces Clinically Meaningful Improvement in Both Progressi...

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial  Hazard Ratios and Improvements in Median PFS areUnprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) reduced the risk of disease progression or death by 76% vs. fulvestrant (HR=0.24; 95% CI: 0.17–0.35; p

July 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch